Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients

被引：53

作者：

Pan, Yi ^{[1
]}

Zhang, Jia-Tao ^{[1
]}

Gao, Xuan ^{[2
]}

Chen, Zhi-Yong ^{[1
]}

Yan, Bingfa

Tan, Pei-Xin ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Gao, Wei ^{[2
]}

Gong, Yuhua ^{[2
]}

Tian, Zihan ^{[2
]}

Liu, Si-Yang Maggie ^{[3
,4
,5
]}

Lin, Hui ^{[1
]}

Sun, Hao ^{[1
]}

Huang, Jie ^{[1
]}

Liu, Si-Yang ^{[1
]}

Yan, Hong-Hong ^{[1
]}

Dong, Song ^{[1
]}

Xu, Chong-Rui ^{[1
]}

Chen, Hua-Jun ^{[1
]}

Wang, Zhen ^{[1
]}

Li, Pansong

Guan, Yanfang ^{[2
]}

Wang, Bin-Chao ^{[1
]}

Yang, Jin-Ji ^{[1
]}

Tu, Hai-Yan ^{[1
]}

Yang, Xue-Ning ^{[1
]}

Zhong, Wen-Zhao ^{[1
]}

Xia, Xuefeng ^{[2
]}

Yi, Xin ^{[2
]}

Zhou, Qing ^{[1
]}

Wu, Yi-Long ^{[1
,5
]}

机构：

[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[2] Geneplus Beijing Inst, Beijing, Peoples R China

[3] Jinan Univ, Affiliated Hosp 1, Inst Hematol, Dept Hematol,Sch Med, Guangzhou, Guangdong, Peoples R China

[4] Jinan Univ, Key Lab Regenerat Med, Minist Educ, Guangzhou, Guangdong, Peoples R China

[5] Chinese Thorac Oncol Grp CTONG, Guangzhou, Guangdong, Peoples R China

来源：

CANCER CELL | 2023年 / 41卷 / 10期

关键词：

MOLECULAR RESIDUAL DISEASE; PLASMA;

D O I：

10.1016/j.ccell.2023.09.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The value of circulating tumor DNA (ctDNA) during chemoradiotherapy (CRT) remains unclear but is critical for detecting molecular residual disease (MRD). In this prospective study, we sequenced 761 blood samples from 139 patients with locally advanced non-small cell lung cancer treated with definitive radiation therapy (RT). ctDNA concentrations showed a significantly declining trend as CRT progressed at on-RT and after-RT time points versus baseline. Thirty-eight (27.3%) patients with early undetectable ctDNA at both on-RT (RT reached 40 Gy) and after-RT time points, indicating early response to CRT, had better survival outcomes for both with or without consolidation immune checkpoint inhibitors. Longitudinal undetectable MRD was found in 20.1% patients. The 2-year cancer-specific progression-free survival of these patients was 88.4%, corresponding to a potentially cured population. Further analysis revealed that pretreatment ctDNA variants serve as an essential MRD informed source. These data provide clinical insights for ctDNA-MRD detection.

引用

页码：1763 / +

页数：16

共 34 条

[1] Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection [J].

Abbosh, Christopher ;

Birkbak, Nicolai J. ;

Swanton, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :577-586

[2] Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression [J].

Aldea, Mihaela ;

Hendriks, Lizza ;

Mezquita, Laura ;

Jovelet, Cecile ;

Planchard, David ;

Auclin, Edouard ;

Remon, Jordi ;

Howarth, Karen ;

Benitez, Jose Carlos ;

Gazzah, Anas ;

Lavaud, Pernelle ;

Naltet, Charles ;

Lacroix, Ludovic ;

de Kievit, Frank ;

Morris, Clive ;

Green, Emma ;

Ngo-Camus, Maud ;

Rouleau, Etienne ;

Massard, Christophe ;

Caramella, Caroline ;

Friboulet, Luc ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) :383-391

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer [J].

Bradley, Jeffrey D. ;

Hu, Chen ;

Komaki, Ritsuko R. ;

Masters, Gregory A. ;

Blumenschein, George R. ;

Schild, Steven E. ;

Bogart, Jeffrey A. ;

Forster, Kenneth M. ;

Magliocco, Anthony M. ;

Kavadi, Vivek S. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Clifford G. ;

Wynn, Raymond B. ;

Koprowski, Christopher D. ;

Olson, Michael R. ;

Meng, Joanne ;

Paulus, Rebecca ;

Curran, Walter J., Jr. ;

Choy, Hak .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) :706-+

[5] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

[6] Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling [J].

Chaudhuri, Aadel A. ;

Chabon, Jacob J. ;

Lovejoy, Alexander F. ;

Newman, Aaron M. ;

Stehr, Henning ;

Azad, Tej D. ;

Khodadoust, Michael S. ;

Esfahani, Mohammad Shahrokh ;

Liu, Chih Long ;

Zhou, Li ;

Scherer, Florian ;

Kurtz, David M. ;

Say, Carmen ;

Carter, Justin N. ;

Merriott, David J. ;

Dudley, Jonathan C. ;

Binkley, Michael S. ;

Modlin, Leslie ;

Padda, Sukhmani K. ;

Gensheimer, Michael F. ;

West, Robert B. ;

Shrager, Joseph B. ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Loo, Billy W., Jr. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

CANCER DISCOVERY, 2017, 7 (12) :1394-1403

[7] Predicting Radiotherapy Responses and Treatment outcomes Through Analysis of Circulating Tumor DNA [J].

Chaudhuri, Aadel A. ;

Binkley, Michael S. ;

Osmundson, Evan C. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

SEMINARS IN RADIATION ONCOLOGY, 2015, 25 (04) :305-312

[8] Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy [J].

Cheng, Chao ;

Omura-Minamisawa, Motoko ;

Kang, Yun ;

Hara, Takamitsu ;

Koike, Izumi ;

Inoue, Tomio .

CANCER SCIENCE, 2009, 100 (02) :303-309

[9] Interstitial lung disease in lung cancer - Separating disease progression from treatment effects [J].

Danson, S ;

Blackhall, F ;

Hulse, P ;

Ranson, M .

DRUG SAFETY, 2005, 28 (02) :103-113

[10] The nf-core framework for community-curated bioinformatics pipelines [J].

Ewels, Philip A. ;

Peltzer, Alexander ;

Fillinger, Sven ;

Patel, Harshil ;

Alneberg, Johannes ;

Wilm, Andreas ;

Garcia, Maxime Ulysse ;

Di Tommaso, Paolo ;

Nahnsen, Sven .

NATURE BIOTECHNOLOGY, 2020, 38 (03) :276-278

← 1 2 3 4 →